Cadrenal Therapeutics receives FDA guidance for CAD-1005 phase 3 trial

May 7, 2026 8:30 AM

Cadrenal Therapeutics Inc. (NASDAQ: CVKD) reported first quarter 2026 financial results and announced it received official minutes from its End-of-Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found